{"analyses":[{"groupDescription":"Null hypothesis of ORR by BICR for cohort A was 38%.","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Exact binominal"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.5","upperLimit":"80.8","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"ORR: % of participants with best overall response of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR \\& normal serum free light chain (sFLC) ratio \\& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \\& urine, disappearance of any soft tissue plasmacytoma \\& \\<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum M-protein \\& urine M-protein level \\<100mg/24h. PR: \\>=50% reduction in serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h. If serum \\& urine M-protein were unmeasurable, VGPR \\& PR: \\>=90% \\& \\>=50% decrease in difference respectively between involved \\& uninvolved sFLC levels \\& if present at baseline, \\>=90% \\& \\>=50% reduction in soft tissue plasmacytomas' size.","dispersionType":"95% Confidence Interval","groups":[{"description":"BCMA-naïve participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Cohort A"}],"paramType":"NUMBER","populationDescription":"Safety analysis set included all enrolled participants who received at least one dose of study intervention. Here, 'Overall Number of Participants Analyzed' signifies number of participants without EMD at baseline. This outcome measure was planned only in Cohort A.","reportingStatus":"POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)","title":"Cohort A Only: Objective Response Rate as Per IMWG Criteria by BICR for Participants Without EMD at Baseline","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}